Certara, Inc. (NASDAQ:CERT) Receives $15.83 Average Target Price from Brokerages

Certara, Inc. (NASDAQ:CERT) has earned a consensus rating of “Moderate Buy” from the eight research firms that are presently covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $15.83.

A number of research firms have recently weighed in on CERT. William Blair restated a “market perform” rating on shares of Certara in a report on Thursday, February 27th. Barclays upped their price target on Certara from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, February 28th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective on the stock. Finally, Stephens reaffirmed an “overweight” rating and set a $17.00 target price on shares of Certara in a research report on Thursday, February 27th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CERT. Venturi Wealth Management LLC grew its stake in shares of Certara by 839.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock worth $30,000 after acquiring an additional 2,509 shares during the last quarter. Wells Fargo & Company MN grew its position in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock worth $34,000 after purchasing an additional 1,047 shares during the last quarter. Johnson Financial Group Inc. bought a new position in shares of Certara during the 4th quarter worth about $47,000. Blue Trust Inc. raised its position in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after buying an additional 822 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of Certara by 48.2% in the third quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares during the period. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Price Performance

NASDAQ CERT opened at $9.91 on Monday. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $1.60 billion, a PE ratio of -49.55, a price-to-earnings-growth ratio of 9.29 and a beta of 1.60. Certara has a 12-month low of $9.41 and a 12-month high of $19.18. The company has a 50 day moving average price of $12.43 and a two-hundred day moving average price of $11.45.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.